With new data, Lilly sets pace for next wave of breast cancer drugs
While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...
STAT14h
Eli Lilly’s new maneuvers in GLP-1 treatment
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...
Senior Housing News4h
Eli Lilly Partners with the Global Alzheimer’s Platform Foundation on Blood Test Study
Global Alzheimer's Platform Foundation (GAP) has partnered with Eli Lilly and Company (NYSE: LLY) for a study comparing blood ...
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts
Eli Lilly announces $15 billion share buyback plan and 15% dividend boost amidst mixed technical signals. Investors are ...
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
As Eli Lilly Shares Gain Over 35% YTD, Drugmaker Announces $15B Share Buyback Program And Boosts Dividend By 15%
According to the announcement, the share repurchase program allows for flexibility in purchasing methods, including open ...
Eli Lilly announces $15B share repurchase program, 15% dividend increase
The board of directors of Eli Lilly (LLY) and Company approved a new $15B share repurchase program. The company’s prior $5B share repurchase ...
STAT13h
Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.